An anonymous director reports

CLEARMIND MEDICINE ANNOUNCES 1-FOR-30 REVERSE SHARE SPLIT

Clearmind Medicine Inc. will conduct a reverse share split of its issued and outstanding ordinary shares, no par value, at a ratio of one for 30. The reverse split is being effected as part of the company's plan to regain compliance with the Nasdaq minimum bid price rule and will be effective commencing Nov. 28, 2023.

The reverse share split was approved by the company's shareholders at the company's general shareholders meeting held on Nov. 14, 2023, and subsequently resolved by the company's board of directors.

Following the implementation of the reverse split, the company's authorized share capital will remain unchanged, which, as of the date hereof, is unlimited. The reverse split will adjust the number of issued and outstanding common shares of the company from 18,221,419 common shares to 607,381 common shares (subject to any further adjustments based on the treatment of fractional shares).

No fractional common shares will be issued as a result of the reverse split. All fractional shares shall be rounded up to the nearest whole common share. In addition, a proportionate adjustment will be made to the per-share exercise price and the number of common shares issuable upon the exercise of all outstanding options or warrants entitling the holders thereof to purchase common shares.

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The company's intellectual portfolio currently consists of 14 patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq and the Canadian Securities Exchange under the symbol CMND and the Frankfurt Stock Exchange under the symbol CWY.

We seek Safe Harbor.